Zyban and Chantix
Zyban is the same as Wellbutrin / buproprion
Active Substance - bupropion hydrochloride
Zyban - aid to smoking cessation in combination with motivational support in nicotine-dependent patients
Wellbutrin - an antidepressant medication used to treat major depressive disorder and seasonal affective disorder
Psychiatric adverse reactions
agitation, depression, and irritability, abnormal coordination, confusion, decreased libido, decreased memory, depersonalization, emotional lability, hostility, hyperkinesia, hypertonia, hypesthesia, paresthesia, suicidal ideation, and vertigo, amnesia, ataxia, derealization, and hypomania.
Also observed in trials were abnormal electroencephalogram (EEG), aggression, akinesia, aphasia, coma, delirium, delusions, dysarthria, dyskinesia, dystonia, euphoria, extrapyramidal syndrome, hallucinations, hypokinesia, increased libido, manic reaction, neuralgia, neuropathy, paranoid ideation, restlessness, and unmasking tardive dyskinesia.
Call your doctor at once if you have any new or worsening symptoms such as: mood or behavior changes, anxiety, panic attacks, trouble sleeping, or if you feel impulsive, irritable, agitated, hostile, aggressive, restless, hyperactive (mentally or physically), more depressed, or have thoughts about suicide or hurting yourself.
Clinical Worsening and Suicide Risk
Patients, their families, and their caregivers should be encouraged to be alert to the emergence of anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia (psychomotor restlessness), hypomania, mania, other unusual changes in behavior, worsening of depression, and suicidal ideation, especially early during antidepressant treatment and when the dose is adjusted up or down.
Families and caregivers of patients should be advised to look for the emergence of such symptoms on a day-to-day basis, since changes may be abrupt. Such symptoms should be reported to the patientís prescriber or health professional, especially if they are severe, abrupt in onset, or were not part of the patientís presenting symptoms.
Risk of suicide Symptoms such as these may be associated with an increased risk for suicidal thinking and behavior and indicate a need for very close monitoring and possibly changes in the medication.
Patients should be made aware that Zyban contains the same active ingredient found in WELLBUTRIN, WELLBUTRIN SR, and WELLBUTRIN XL used to treat depression and that Zyban should not be used in conjunction with WELLBUTRIN, the immediate-release formulation; WELLBUTRIN SR, the sustained-release formulation; WELLBUTRIN XL, the extended-release formulation; or any other medications that contain bupropion hydrochloride.
UK statistics for Zyban (2008)
20.000 have reported suspected adverse reactions in Britain
81 deaths reported out which 6 were suicides
99 suicidal ideation
Medicines information from the manufacturer
If you have suffered a psychiatric adverse reactions to this drug please report them via The Yellow Card as well email APRIL (please menu on left for information about reporting)
Active Ingredient: varenicline (as tartrate)
Indication - Smoking cessation in adults
Psychiatric Side Effects
Nausea, difficulty sleeping, abnormal dreams, dysphoric or depressed mood; insomnia, irritability, frustration or anger, anxiety, difficulty concentrating, restlessness
FDA Warnings Suicidal ideation and behaviour
November 2007 - FDA announced it had received post-marketing reports that patients using Chantix for smoking cessation had experienced several serious symptoms, including suicidal ideation and occasional suicidal behaviour, erratic behavior, and drowsiness.
February 1, 2008 FDA - Neuropsychiatric symptoms have occurred in patients being treated with Chantix. Some cases may have been complicated by the symptoms of nicotine withdrawal in patients who stopped smoking; however, some of these symptoms have occurred in patients who continued to smoke.
All patients being treated with Chantix should be observed for neuropsychiatric symptoms including changes in behavior, agitation, depressed mood, suicidal ideation and suicidal behavior.
These symptoms, as well as worsening of pre-existing psychiatric illness, have been reported in patients attempting to quit smoking while taking Chantix in the postmarketing experience.
At the end of treatment, discontinuation of CHAMPIX was associated with an increase in irritability, urge to smoke, depression, and/or insomnia in up to 3% of patients. The prescriber should inform the patient accordingly and discuss or consider the need for dose tapering
Related Information and Articles
Some patients' reports
If you have suffered a psychiatric adverse reactions to this drug please report them via The Yellow Card as well email APRIL (please see menu on left for more information about reporting)
Please submit a Yellow Card report to the regulator (MHRA)
APPEAL FOR YOUR HELP !
Have you been helped in any way by APRIL?
If so please tell us.